Microfabricated Engineered Particle Systems for Respiratory Drug Delivery and Other Pharmaceutical Applications

Figure 4

Favorable properties of PRINT aerosols for dry powder pharmaceutical use. (a, b) Comparison of 1.5 μm torus PRINT-zanamivir particles against the marketed product Relenza (active pharmaceutical ingredient zanamivir) using an NGI. (b) PS: preseparator; RSD: relative standard deviation. (c) Whole lung deposition by gamma scintigraphy in canine shows increased whole-lung deposition of 1.5 μm (right, 1.3 μm MMAD) torus aerosols versus 6.0 μm (left, 4.6 μm MMAD) torus aerosols.

(a)

(b)

(c)